Cargando…

Pirfenidone improves survival in IPF: results from a real-life study

BACKGROUND: Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone’s effect on mortality and adverse events profile outside the restrictions of a clinical trial. METHODS: This is a retros...

Descripción completa

Detalles Bibliográficos
Autores principales:	Margaritopoulos, George A., Trachalaki, Athina, Wells, Athol U., Vasarmidi, Eirini, Bibaki, Eleni, Papastratigakis, George, Detorakis, Stathis, Tzanakis, Nikos, Antoniou, Katerina M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251092/ https://www.ncbi.nlm.nih.gov/pubmed/30470213 http://dx.doi.org/10.1186/s12890-018-0736-z

Ejemplares similares

Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF
por: Tsitoura, Eliza, et al.
Publicado: (2019)

Investigation of key autophagy-and mitophagy-related proteins and gene expression in BALF cells from patients with IPF and RA-ILD
por: Vasarmidi, Eirini, et al.
Publicado: (2018)

miR-185 and miR-29a are similarly expressed in the bronchoalveolar lavage cells in IPF and lung cancer but common targets DNMT1 and COL1A1 show disease specific patterns
por: Bibaki, Eleni, et al.
Publicado: (2018)

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy
por: Margaritopoulos, George A, et al.
Publicado: (2016)

Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality
por: Tsitoura, Eliza, et al.
Publicado: (2021)

MiR-185/AKT and miR-29a/Collagen 1a pathways are activated in IPF BAL cells
por: Tsitoura, Eliza, et al.
Publicado: (2016)

Upregulation of citrullination pathway: From Autoimmune to Idiopathic Lung Fibrosis
por: Samara, Katerina D., et al.
Publicado: (2017)

Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis
por: Trachalaki, Athina, et al.
Publicado: (2021)

Smoking and interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2015)

Paroxysmal cough and left sacroiliac joint pain in a 50-year-old Caucasian man
por: Proklou, Athanasia, et al.
Publicado: (2018)

[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver
por: Tsitoura, Eliza, et al.
Publicado: (2020)

Assembly 12: interstitial lung diseases
por: Antoniou, Katerina, et al.
Publicado: (2018)

Comorbidities in interstitial lung diseases
por: Margaritopoulos, George A., et al.
Publicado: (2017)

Smoking and Pulmonary Fibrosis: Novel Insights
por: Samara, Katerina D., et al.
Publicado: (2011)

Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study
por: Antoniou, Katerina, et al.
Publicado: (2020)

Pulmonary fibrosis in the aftermath of the COVID-19 era (Review)
por: Vasarmidi, Eirini, et al.
Publicado: (2020)

Self-Eating: Friend or Foe? The Emerging Role of Autophagy in Idiopathic Pulmonary Fibrosis
por: Margaritopoulos, George A., et al.
Publicado: (2013)

Investigation of Telomerase/Telomeres system in Bone Marrow Mesenchymal Stem Cells derived from IPF and RA-UIP
por: Antoniou, Katerina M, et al.
Publicado: (2012)

Rapidly non-ipf progressive fibrosing interstitial lung disease: a phenotype with an ipf-like behavior
por: Khine, Ngu, et al.
Publicado: (2020)

Analyses of the Efficacy and Safety of Antifibrotic Therapies in Non-IPF Pulmonary Fibrosis, Progressing Despite Management
por: Wells, Athol U.
Publicado: (2022)

NLRP3/Caspase-1 inflammasome activation is decreased in alveolar macrophages in patients with lung cancer
por: Lasithiotaki, Ismini, et al.
Publicado: (2018)

The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF) - practical implications
por: Wells, Athol U
Publicado: (2013)

Clinical applications of mesenchymal stem cells in chronic lung diseases
por: Antoniou, Katerina M., et al.
Publicado: (2018)

Personalised medicine in interstitial lung diseases: Number 6 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
por: Kokosi, Maria A., et al.
Publicado: (2018)

IPF Care: A Support Program for Patients with Idiopathic Pulmonary Fibrosis Treated with Pirfenidone in Europe
por: Duck, Annette, et al.
Publicado: (2015)

Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
por: Molina-Molina, M., et al.
Publicado: (2018)

Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
por: Vu, Tuong N., et al.
Publicado: (2019)

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry
por: Zurkova, Monika, et al.
Publicado: (2019)

Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study
por: Lee, Eung Gu, et al.
Publicado: (2021)

Sarcoidosis in a 65-year-old woman presenting with a lung mass and pericardial effusion: a case report
por: Margaritopoulos, George A, et al.
Publicado: (2012)

Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg)
por: Krauss, Ekaterina, et al.
Publicado: (2020)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
por: Finnerty, James Patrick, et al.
Publicado: (2021)

Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
por: Kang, Jieun, et al.
Publicado: (2023)

Adult Onset Still's Disease: A Case Report with a Rare Clinical Manifestation and Pathophysiological Correlations
por: Antoniou, Katerina M., et al.
Publicado: (2013)

Serial Decline in Lung Volume Parameters on Computed Tomography (CT) Predicts Outcome in Idiopathic Pulmonary Fibrosis (IPF)
por: Robbie, Hasti, et al.
Publicado: (2022)

Historical eye on IPF: a cohort study redefining the mortality scenario
por: Tomassetti, Sara, et al.
Publicado: (2023)

Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study
por: Tzilas, Vasilios, et al.
Publicado: (2020)

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
por: Raman, Lavanya, et al.
Publicado: (2023)

Assessing feasibility of targeted primary care referrals for patients with clinical suspicion of interstitial lung disease using lung ultrasound: A prospective case finding study. The potential benefits of LUS utilization
por: Symvoulakis, Emmanouil K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c3jf3c0dp9sv6nts0bipq9usga